Joseph A. Caruso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph A. Caruso has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Khandan Keyomarsi
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
57 shared publications - Kelly K. Hunt
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
56 shared publications - Amriti R. Lulla
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
54 shared publications - Cansu Karakas
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
54 shared publications - Jing Wang
The University of Texas MD Anderson Cancer Center 2 Department of Bioinformatics and Computational Biology Houston, Texas
54 shared publications - Lucas D. Warma
Van der Waals-Zeeman Institute, Institute of Physics, University of Amsterdam , Amsterdam
54 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S2: (A) Percentage of tumor-free mice in PyMT NE+/+ (N=30) and PyMT NE-/- (N=21) mice, between 12-14 weeks of age. (B) Total tumor mass, (C) number of glands with tumors per mouse and (D) doubling time of tumors at end point (12-14 weeks age) in PyMT NE+/+ & PyMT NE-/- mice. (E) Frequency of the major histologies (solid, alveolar/tubular, papillary, and adenosquamous) detected in both PyMT NE+/+ and PyMT NE-/- primary tumors. (F) Spontaneous tumors isolated from PyMT NE+/+ and PyMT NE-/- mice were implanted in FVB NE+/+ and FVB NE-/- respectively. Tumor growth curves, as a function of days post implantation are shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S2: (A) Percentage of tumor-free mice in PyMT NE+/+ (N=30) and PyMT NE-/- (N=21) mice, between 12-14 weeks of age. (B) Total tumor mass, (C) number of glands with tumors per mouse and (D) doubling time of tumors at end point (12-14 weeks age) in PyMT NE+/+ & PyMT NE-/- mice. (E) Frequency of the major histologies (solid, alveolar/tubular, papillary, and adenosquamous) detected in both PyMT NE+/+ and PyMT NE-/- primary tumors. (F) Spontaneous tumors isolated from PyMT NE+/+ and PyMT NE-/- mice were implanted in FVB NE+/+ and FVB NE-/- respectively. Tumor growth curves, as a function of days post implantation are shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
The file contains NMR spectrometry, LC-MS and HPLC analyses was performed to confirm the purity of and the metabolites profile of AZD9668
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
The file contains NMR spectrometry, LC-MS and HPLC analyses was performed to confirm the purity of and the metabolites profile of AZD9668
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
List of antibodies used in all the flow cytometric analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
List of antibodies used in all the flow cytometric analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S5: Reverse Phase Protein Array (RPPA) analysis was conducted on TAN negative and TAN positive patient samples described in Figure 1, using 174 validated antibodies. The mean of the normalized, linear RPPA values are reported for each group. (A) Relative abundance of pp90RSK T359/S363 and pRb S807 in TAN negative and TAN positive patient samples. (B) The table summarizes the top 20 antibodies that were statistically altered between the TAN negative and TAN positive groups. Statistical comparisons of TAN-positive and TAN-negative cohorts were performed using the Mann-Whitney U-test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S5: Reverse Phase Protein Array (RPPA) analysis was conducted on TAN negative and TAN positive patient samples described in Figure 1, using 174 validated antibodies. The mean of the normalized, linear RPPA values are reported for each group. (A) Relative abundance of pp90RSK T359/S363 and pRb S807 in TAN negative and TAN positive patient samples. (B) The table summarizes the top 20 antibodies that were statistically altered between the TAN negative and TAN positive groups. Statistical comparisons of TAN-positive and TAN-negative cohorts were performed using the Mann-Whitney U-test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S10: Gating strategy used to identify myeloid, lymphoid and B-cell populations for the experiment described in Supplementary Figure S2. All analyses were conducted on FlowJo and statistical analyses were done on GraphPad Prism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S10: Gating strategy used to identify myeloid, lymphoid and B-cell populations for the experiment described in Supplementary Figure S2. All analyses were conducted on FlowJo and statistical analyses were done on GraphPad Prism.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods 1 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Materials and Methods, clean copy version
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods 1 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Materials and Methods, clean copy version
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S7: Recurrence-free survival (A) and overall survival (C) for each individual gene used in the METABRIC patient cohort signature and progression-free survival (B) and overall survival (D) used in the and TCGA patient cohort signature.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S7: Recurrence-free survival (A) and overall survival (C) for each individual gene used in the METABRIC patient cohort signature and progression-free survival (B) and overall survival (D) used in the and TCGA patient cohort signature.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Immune subsets and their associated cell surface markers used for gating in flow cytometric analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Immune subsets and their associated cell surface markers used for gating in flow cytometric analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S9: Human TNBC cell lines MDA-MB-231 and MDA-MB-468 were injected in the T4 mammary fat pad of 12 week old nude mice. When tumors reached size of 100mm3, mice were randomized in Vehicle and AZD9668 100mg/kg groups. Mice were then treated daily B.I.D until the endpoint of Vehicle tumors reaching 2000mm3. (A, B) Tumor growth curves of mice treated with either Vehicle or AZD9668 100mg/kg in the MDA-MB-231 and MDA- MB-468 models respectively. Endpoint tumors harvested were subject to BrdU staining. (C, D) Representative images BrdU staining and (E, F) their corresponding quantitation in the MDA- MB-231 and MDA-MB-468 models respectively. (G) Spontaneous tumors isolated from PyMT NE+/+ were implanted in FVB NE+/+ mice. When tumors reached a measurable size of 30- 50mm3, mice were randomized into Vehicle and AZD9668 100mg/kg group and treated B.I.D until 400-500mm3. Tumor growth curves, as a function of time are shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Supplementary Figure S9: Human TNBC cell lines MDA-MB-231 and MDA-MB-468 were injected in the T4 mammary fat pad of 12 week old nude mice. When tumors reached size of 100mm3, mice were randomized in Vehicle and AZD9668 100mg/kg groups. Mice were then treated daily B.I.D until the endpoint of Vehicle tumors reaching 2000mm3. (A, B) Tumor growth curves of mice treated with either Vehicle or AZD9668 100mg/kg in the MDA-MB-231 and MDA- MB-468 models respectively. Endpoint tumors harvested were subject to BrdU staining. (C, D) Representative images BrdU staining and (E, F) their corresponding quantitation in the MDA- MB-231 and MDA-MB-468 models respectively. (G) Spontaneous tumors isolated from PyMT NE+/+ were implanted in FVB NE+/+ mice. When tumors reached a measurable size of 30- 50mm3, mice were randomized into Vehicle and AZD9668 100mg/kg group and treated B.I.D until 400-500mm3. Tumor growth curves, as a function of time are shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’ Influence in Breast Cancer RFS (n=242)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’ Influence in Breast Cancer RFS (n=242)